Molly Gale

Molly Gale has worked in a variety of roles in the scientific field since 2010. Molly began their career as an Intern at the Banner Sun Health Research Institute: Center for Cardiovascular Research in 2010. From 2011 to 2012, they worked as a Research Associate I/ Intern at TGen - an Affiliate of City of Hope, where they characterized DNA methylation and gene expression in multiple myeloma cells, examined the effects of a mutation (E17K) of AKT1 in breast cells, and investigated a particular histone demethylase as a novel drug target for multiple myeloma. From 2012 to 2019, they worked at Yale University as a PhD Student Researcher, where they discovered novel small molecule inhibitors of lysine demethylase KDM5A through a high throughput screen, evaluated their efficacy at stopping cancer cell growth and anti-cancer drug resistance, and examined their mechanism of action. Molly also investigated resistance to HER2-targeted antibodies in breast cancer, identified pathways involved through RNA sequencing, and examined metabolic changes associated with resistance. Additionally, they performed an RNA interference screen to identify novel epigenetic regulators of resistance. Finally, since 2019, they have been working as a Scientist II at Rubedo Life Sciences.

Molly Gale received a Bachelor of Science (B.S.) in Biology, General from the University of Arizona between 2006 and 2010. Molly then went on to complete their Doctor of Philosophy (Ph.D.) in Experimental Pathology from Yale University between 2012 and 2018.